Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

NICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in first draft guidance, citing uncertainties with evidence.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a supplemental Biologics License Application for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP), a ...

constipation, upper respiratory tract infection, limb injury, and insomnia, according to Sanofi. The dupilumab studies were funded by Sanofi and Regeneron, the companies co-developing dupilumab.

Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA) to treat adults with bullous pemphigoid (BP). BP is a chronic and ...

Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive ...

and Sanofi today presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent ® (dupilumab) in adults with moderate-to-severe bullous ...

By targeting the IL-4 beta receptor and IL-13, the researchers said, dupilumab (Dupixent; Sanofi, Regeneron) manages atopic dermatitis and improves depression and anxiety, but evidence about its ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than ...

and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ® (dupilumab ...